Clinical trials in Hoofddorp – page 127

1 940 clinical trials in Hoofddorp, The Netherlands across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in the NetherlandsKlinischOnderzoek.nl

Hoofddorp at a glance

1 940

clinical trials

Research sites1

Quick filters

1 940 trials in Hoofddorp

Open in trial search

Gastroenteropancreatic neuroendocrine tumour disease

Not recruiting

Study on RYZ101 for Patients with Advanced Gastroenteropancreatic Neuroendocrine Tumors After Previous Treatment

Registered drugNo placebo

Study on RYZ101 for Patients with Advanced Gastroenteropancreatic Neuroendocrine Tumors After Previous Treatment

Registered drugNo placebo

The Netherlands

Participants:18–64 years
Substances:Everolimus
Sponsor:Rayzebio Inc.

Contact Research Centre

Gastrooesophageal cancer+5

Not recruiting

Study of Nivolumab or Placebo for Patients with Removed Esophageal or Gastroesophageal Junction Cancer

Registered drug

Study of Nivolumab or Placebo for Patients with Removed Esophageal or Gastroesophageal Junction Cancer

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Nivolumab
Sponsor:Bristol Myers Squibb International Corporation

Contact Research Centre

Progressive supranuclear palsy

Not recruiting

Study on the Effects of AMX0035 (Phenylbutyrate and Ursodoxicoltaurine) in Patients with Progressive Supranuclear Palsy

Investigational

Study on the Effects of AMX0035 (Phenylbutyrate and Ursodoxicoltaurine) in Patients with Progressive Supranuclear Palsy

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:Phenylbutyrate
Sponsor:Amylyx Pharmaceuticals Inc.

Contact Research Centre

Breast cancer

Not recruiting

Study on Olaparib for Patients with High-Risk HER2-Negative Breast Cancer and BRCA1/2 Mutations After Chemotherapy

Registered drug

Study on Olaparib for Patients with High-Risk HER2-Negative Breast Cancer and BRCA1/2 Mutations After Chemotherapy

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Olaparib
Sponsor:AstraZeneca AB

Contact Research Centre

Ovarian cancer

Not recruiting

Study of Olaparib for Patients with Advanced BRCA-Mutated Ovarian Cancer After Initial Platinum-Based Chemotherapy

Registered drug

Study of Olaparib for Patients with Advanced BRCA-Mutated Ovarian Cancer After Initial Platinum-Based Chemotherapy

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Olaparib
Sponsor:AstraZeneca AB

Contact Research Centre

Atrial fibrillation+1

Not recruiting

Study on Rivaroxaban for Patients with Atrial Fibrillation and Coronary Artery Disease After Heart Procedure

Registered drugNo placebo

Study on Rivaroxaban for Patients with Atrial Fibrillation and Coronary Artery Disease After Heart Procedure

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Rivaroxaban
Sponsor:Amsterdam UMC Stichting

Contact Research Centre

Prostate cancer metastatic

Not recruiting

Study of AZD5305 with Abiraterone Acetate and Darolutamide in Men with Metastatic Castration-Sensitive Prostate Cancer

Registered drug

Study of AZD5305 with Abiraterone Acetate and Darolutamide in Men with Metastatic Castration-Sensitive Prostate Cancer

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Abiraterone Acetate
Sponsor:AstraZeneca AB

Contact Research Centre

Chronic kidney disease+1

Not recruiting

Study on Finerenone for Children with Chronic Kidney Disease and Proteinuria Using ACEI or ARB

Investigational

Study on Finerenone for Children with Chronic Kidney Disease and Proteinuria Using ACEI or ARB

Investigational

The Netherlands

Participants:0–17 years
Substances:Finerenone
Sponsor:Bayer AG

Contact Research Centre

Cervix carcinoma

Not recruiting

Study of LN-145 (tumor infiltrating lymphocytes) with cyclophosphamide, fludarabine, and aldesleukin in patients with recurrent, metastatic, or persistent cervical cancer

Registered drugNo placebo

Study of LN-145 (tumor infiltrating lymphocytes) with cyclophosphamide, fludarabine, and aldesleukin in patients with recurrent, metastatic, or persistent cervical cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Aldesleukin
Sponsor:Iovance Biotherapeutics Inc.

Contact Research Centre

Plasma cell myeloma+1

Not recruiting

Study Comparing Ciltacabtagene Autoleucel with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed and Lenalidomide-Refractory Multiple Myeloma

Registered drugNo placebo

Study Comparing Ciltacabtagene Autoleucel with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed and Lenalidomide-Refractory Multiple Myeloma

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Bortezomib
Sponsor:Janssen Cilag International

Contact Research Centre

Renal cell carcinoma

Not recruiting

Study of Belzutifan with Lenvatinib versus Cabozantinib in Adults with Advanced Renal Cell Carcinoma Who Have Previously Received Anti-PD-1/L1 Treatment

Registered drugNo placebo

Study of Belzutifan with Lenvatinib versus Cabozantinib in Adults with Advanced Renal Cell Carcinoma Who Have Previously Received Anti-PD-1/L1 Treatment

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Belzutifan
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Spinal muscular atrophy

Not recruiting

Study on Long-Term Safety and Effects of Apitegromab in Patients with Type 2 and TYPE 3 Spinal Muscular Atrophy Who Completed Previous Trials

InvestigationalNo placebo

Study on Long-Term Safety and Effects of Apitegromab in Patients with Type 2 and TYPE 3 Spinal Muscular Atrophy Who Completed Previous Trials

InvestigationalNo placebo

The Netherlands

Participants:0–17 years · 18–64 years
Substances:Apitegromab
Sponsor:Scholar Rock Inc.

Contact Research Centre

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Hoofddorp

What the registry says about research in the country

01 Oncology Research

Extensive research focusing on various cancer types including breast cancer, bladder cancer, and melanoma. Studies are evaluating novel treatment combinations and maintenance therapies for improved patient outcomes.

Advanced/Metastatic Breast Cancer Treatments
Urothelial Cancer Therapies
Hematologic Malignancies

Multiple trials are investigating innovative approaches for both solid tumors and blood cancers, with particular emphasis on targeted therapies.

02 Hematologic Disorders

Comprehensive studies examining treatments for various blood disorders, including chronic myeloid leukemia, myelofibrosis, and lymphomas. Focus on developing targeted therapies and combination treatments.

B-Cell Lymphoma Treatments
Myelofibrosis Therapies
Leukemia Management

Research aims to improve treatment outcomes and quality of life for patients with blood disorders.

03 Metabolic and Surgical Studies

Research initiatives addressing obesity management and surgical conditions like appendicitis. Studies include weight management therapies and surgical technique improvements.

Weight Management Interventions
Surgical Techniques
Prevention Studies

Trials focus on both therapeutic and surgical interventions for better patient outcomes.

Back to the Netherlands All countries